Active substance
Edoxaban
- US FDA 1
- Health Canada 10
- US price lines 2
- NHS prices 3
- WHO EML 1
- Safety 7
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SAVAYSA | EQ 15MG BASE; EQ 30MG BASE; EQ 60MG BASE | tablet · oral | DAIICHI SANKYO INC | Prescription | 8 Jan 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| JAMP EDOXABAN | 02557282 | 30 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP EDOXABAN | 02557290 | 60 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| PRO-EDOXABAN | 02556960 | 30 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PRO-EDOXABAN | 02556979 | 60 MG | TABLET · ORAL | PRO DOC LIMITEE |
| SANDOZ EDOXABAN | 02553414 | 15 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ EDOXABAN | 02553422 | 30 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ EDOXABAN | 02553430 | 60 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| TEVA-EDOXABAN | 02554208 | 15 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-EDOXABAN | 02554216 | 30 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-EDOXABAN | 02554224 | 60 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SAVAYSA 30 MG TABLET | $15.4815 | per EA | 1 Jul 2026 |
| US NADAC | SAVAYSA 60 MG TABLET | $15.51152 | per EA | 1 Jul 2026 |
| NHS Drug Tariff | Edoxaban 15mg tablets | £17.50 | 10 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Edoxaban 30mg tablets | £49.00 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Edoxaban 60mg tablets | £49.00 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 10.2. Medicines affecting coagulation · core
Therapeutic equivalent to dabigatran for Other specified atrial fibrillation; Therapeutic equivalent to dabigatran for Venous thromboembolism
Safety signals and safety-related labeling changes
- US FDA 18 Oct 2023 SAVAYSA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 11 Apr 2019 PRAC signal: Recurrent thrombosis in patients with antiphospholipid syndrome
Action for MAH: update of the product information: Yes - EMA PRAC 31 Oct 2018 PRAC signal: Recurrent thrombosis in patients with antiphospholipid syndrome
Action for MAH: update of the product information: No - EMA PRAC 17 May 2018 PRAC signal: Drug interaction between apixaban or edoxaban and selective serotonin reuptake inhibitors and/or serotonin reuptake inhibitors leading to increased risk of bleeding
Action for MAH: update of the product information: Yes - EMA PRAC 8 Feb 2018 PRAC signal: Cholesterol embolisms
Action for MAH: update of the product information: No - EMA PRAC 11 Jan 2018 PRAC signal: Drug interaction between apixaban or edoxaban and selective serotonin reuptake inhibitors and/or serotonin reuptake inhibitors leading to increased risk of bleeding
Action for MAH: update of the product information: No - EMA PRAC 29 Sep 2017 PRAC signal: Cholesterol embolisms
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.